-

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in November 2024.

Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer and Head of Development, and Robert Plenge, M.D., Ph.D., Executive Vice President, Chief Research Officer, will take part in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference. They will answer questions about the company beginning at 10:00 a.m. ET on November 11, 2024.

David Elkins, Executive Vice President, Chief Financial Officer, will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on November 19, 2024. He will answer questions about the company beginning at 9:30 a.m. GMT (U.K.).

Investors and the general public are invited to listen to both sessions at their respective times by visiting http://investor.bms.com. An archived edition of each session will be available following its conclusion.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, X (formerly Twitter), YouTube, Facebook, and Instagram.

corporatefinancial-news

Bristol Myers Squibb

NYSE:BMY

Release Summary
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Release Versions

More News From Bristol Myers Squibb

Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

PRINCETON, N.J.--(BUSINESS WIRE)--BMS Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos in Adolescents with Symptomatic oHCM...

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

PRINCETON, N.J.--(BUSINESS WIRE)--Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy....

Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)

PRINCETON, N.J.--(BUSINESS WIRE)--BMS Reinforces Leadership in oHCM with New Camzyos Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)...
Back to Newsroom